CFTR and cystic fibrosis: Only two studies in humans assessed the effects of ivacaftor on inflammatory marker’s levels in sputum from CF patients carrying the mutation G551D (10, 11), and a more recent one focused on the effect of CFTR-modulator combinations, ivacaftor/lumacaftor and ivacaftor/tezacaftor, on the inflammatory response in serum from F508del-homozygous CF patients (12).